Phase 2 Study of V565, Anti-TNF Antibody, in Crohn’s Patients Begins

Phase 2 Study of V565, Anti-TNF Antibody, in Crohn’s Patients Begins
VHsquared announced the first patients have entered HARBOR, an international Phase 2 clinical trial examining the efficacy of V565 ( an anti-TNFα oral antibody) in treating Crohn’s disease. The study is currently recruiting patients. HARBOR is a randomized, double-blind and placebo-controlled study (NCT02976129) investigating the efficacy, safety, and tolerability of six weeks treatment with V565 in more

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *